Description
- Chemical name: (17β)-3-Oxoandrosta-1,4-dien-17-yl undec-10-enoate
- Formula: C30H44O3
- Anabolic activity index: 100%
- Androgenic activity index: 50%
PHARMABOLD 500 - PHARMACOM LABS
1 vial x 10 ml x 500 mg/ml
Our enhanced version of PHARMABOLD 300 represents a significant advancement, utilizing high-percentage drug synthesis technologies to create a nearly double-concentrated formula compared to the original PHARMABOLD 300. This modification aims to provide athletes with a more potent and efficient option for achieving their fitness goals.
History and Development:
- Modified Formulation: A refined iteration of PHARMABOLD 300, achieved through advanced drug synthesis technologies.
- Origins of Boldenone: Developed as a prolonged version of methandienone and patented by Ciba in 1949 as a synthetic anabolic steroid.
- Original Purpose: Initially intended for treating dystrophy and increasing bone weight and density in osteoporosis.
Benefits:
- High Concentration: Almost double the concentration compared to PHARMABOLD 300.
- Strong Anabolic Properties: Exhibits robust anabolic and moderate androgenic characteristics.
- Low Androgenic Impact for Women: Suitable for female use with a low risk of virilization.
- Stimulation of Hematopoiesis: Promotes increased red blood cell production, enhancing oxygen delivery to muscles.
- Muscle Growth: Induces slow but substantial lean muscle growth, especially noticeable in long cycles (12 weeks or more).
- Muscle Density: Muscles developed on a boldenone cycle are denser compared to those on testosterone.
- Appetite and Power Increase: Significantly raises appetite and enhances power rate.
Warning and Dosage Instructions:
- High Concentration Usage: For first-time use of a high-concentrated drug, inject only ½ ml initially to monitor body reactions and prevent potential side effects.
- Possible Side Effects: Side effects may include post-injection pain (PIP), elevated body temperature, and lumps.
- Mitigation Strategies: Learn how to mitigate post-injection pain HERE.
